176 related articles for article (PubMed ID: 29243246)
1. Patients not patents: Drug research and development as a public enterprise.
Gøtzsche PC
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29243246
[No Abstract] [Full Text] [Related]
2. Evidence Europe 2017. London, UK - February 22-23, 2017.
Kibble A
Drugs Today (Barc); 2017 Mar; 53(3):203-207. PubMed ID: 28447077
[TBL] [Abstract][Full Text] [Related]
3. Introduction: pharmaceutical innovation: law & the public's health.
Outterson K
J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
[No Abstract] [Full Text] [Related]
4. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
5. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
Giri I; Rouillon F
Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
[No Abstract] [Full Text] [Related]
6. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
7. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
8. Pharmaceutical pricing conundrum: time to get rid of it?
Garattini L; Padula A
Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
10. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
11. The Impact of Off-Patent Drug Acquisitions on Prices.
Gupta R; Henkel A; Forman HP; Ross JS
J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
[No Abstract] [Full Text] [Related]
12. Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
Price WN; Minssen T
Nat Biotechnol; 2015 Jul; 33(7):685-6. PubMed ID: 26154001
[No Abstract] [Full Text] [Related]
13. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
Lexchin J
Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
[TBL] [Abstract][Full Text] [Related]
14. A cheat sheet to navigate the complex maze of exclusivities in the United States.
Peng B; Tomas MC
Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
[No Abstract] [Full Text] [Related]
15. Regulation of clinical research sponsored by pharmaceutical companies: a proposal.
Sotelo J
PLoS Med; 2006 Jul; 3(7):e306. PubMed ID: 16805651
[TBL] [Abstract][Full Text] [Related]
16. Patent lifecycle management strategies in open innovation projects.
Lee Y; Fong EA
Drug Discov Today; 2020 Oct; 25(10):1782-1785. PubMed ID: 32592662
[TBL] [Abstract][Full Text] [Related]
17. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
18. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
19. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
20. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
